毕得医药
(688073)
| 流通市值：63.62亿 | | | 总市值：63.62亿 |
| 流通股本：9088.29万 | | | 总股本：9088.29万 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 1,051,265,091.19 | 682,837,408.72 | 323,276,733.74 | 1,323,810,726.7 |
| 营业总成本 | 820,928,608.08 | 533,913,560.35 | 262,853,915.44 | 1,107,810,422.06 |
| 其他经营收益 | | | | |
| 营业利润 | 208,359,617.12 | 137,180,095.94 | 61,695,880.68 | 196,498,103.92 |
| 利润总额 | 208,101,608.95 | 136,955,304.62 | 61,379,932.03 | 195,427,483.42 |
| 净利润 | 163,935,001.09 | 103,303,996.81 | 46,829,140.4 | 151,739,651.59 |
| 每股收益 | | | | |
| 其他综合收益 | 5,080,381.7 | 4,409,705.66 | 3,042,449.36 | 6,977,647.18 |
| 综合收益总额 | 169,015,382.79 | 107,713,702.47 | 49,871,589.76 | 158,717,298.77 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 2,386,120,982.38 | 2,299,286,033 | 2,346,333,126.05 | 2,304,824,720.62 |
| 非流动资产: | | | | |
| 非流动资产合计 | 194,501,404.39 | 190,259,857.03 | 195,797,355.28 | 211,973,168.88 |
| 资产总计 | 2,580,622,386.77 | 2,489,545,890.03 | 2,542,130,481.33 | 2,516,797,889.5 |
| 流动负债: | | | | |
| 流动负债合计 | 309,048,603.42 | 308,151,452.02 | 315,909,520.3 | 341,819,464.7 |
| 非流动负债: | | | | |
| 非流动负债合计 | 112,353,338.03 | 119,564,890.92 | 126,253,418.6 | 129,583,419.42 |
| 负债合计 | 421,401,941.45 | 427,716,342.94 | 442,162,938.9 | 471,402,884.12 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,159,220,445.32 | 2,061,829,547.09 | 2,099,967,542.43 | 2,045,395,005.38 |
| 股东权益合计 | 2,159,220,445.32 | 2,061,829,547.09 | 2,099,967,542.43 | 2,045,395,005.38 |
| 负债和股东权益合计 | 2,580,622,386.77 | 2,489,545,890.03 | 2,542,130,481.33 | 2,516,797,889.5 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,201,976,322.09 | 773,196,684.17 | 363,417,116.61 | 1,480,900,323.86 |
| 经营活动现金流出小计 | 1,016,258,031.04 | 681,571,175.23 | 323,986,198.87 | 1,452,576,108.55 |
| 经营活动产生的现金流量净额 | 185,718,291.05 | 91,625,508.94 | 39,430,917.74 | 28,324,215.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,785,927,997.56 | 1,401,262,426.18 | 481,389,716.42 | 4,261,007,851.79 |
| 投资活动现金流出小计 | 2,118,837,889.4 | 1,433,669,475.92 | 573,540,477.34 | 4,336,155,494.78 |
| 投资活动产生的现金流量净额 | -332,909,891.84 | -32,407,049.74 | -92,150,760.92 | -75,147,642.99 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 30,868,100.56 | 5,021,160.56 | 137,099.4 | 255,691,856.85 |
| 筹资活动现金流出小计 | 119,277,764.25 | 111,223,959.59 | 7,036,223.55 | 393,726,882.94 |
| 筹资活动产生的现金流量净额 | -88,409,663.69 | -106,202,799.03 | -6,899,124.15 | -138,035,026.09 |
| 汇率变动对现金及现金等价物的影响 | -26,833,616.84 | -19,874,630 | -8,910,177.57 | -8,774,772.59 |
| 现金及现金等价物净增加额 | -262,434,881.32 | -66,858,969.83 | -68,529,144.9 | -193,633,226.36 |
| 期末现金及现金等价物余额 | 640,552,590.57 | 836,128,502.06 | 834,458,326.99 | 902,987,471.89 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -66,858,969.83 | - | -193,633,226.36 |
最新报告期：2026-09-23| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华创证券 | 郑辰 | 2.44 | 3.29 | 3.97 | 2026-09-23 |
| 西部证券 | 李梦园 | 2.43 | 3.09 | 4.05 | 2026-09-15 |
| 浙商证券 | 胡隽扬 | 2.36 | 2.99 | 3.64 | 2026-09-08 |